The SGLT2 inhibitors class of diabetes drugs appear to increase the risk of gangrene of the genital area, a rare but potentially fatal side effect. The FDA found 55 cases of the condition, called Fournier gangrene, in people taking three common types of SGTL2 inhibitors, between March 2013 and January 2019. Read more